168 related articles for article (PubMed ID: 38767930)
1. Antipsychotic Medication Continuation vs Taper and Discontinuation in Patients With Schizophrenia and Other Nonaffective Psychotic Disorders.
Andrade C
J Clin Psychiatry; 2024 May; 85(2):. PubMed ID: 38767930
[TBL] [Abstract][Full Text] [Related]
2. To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial.
Begemann MJH; Thompson IA; Veling W; Gangadin SS; Geraets CNW; van 't Hag E; Müller-Kuperus SJ; Oomen PP; Voppel AE; van der Gaag M; Kikkert MJ; Van Os J; Smit HFE; Knegtering RH; Wiersma S; Stouten LH; Gijsman HJ; Wunderink L; Staring ABP; Veerman SRT; Mahabir AGS; Kurkamp J; Pijnenborg GHM; Veen ND; Marcelis M; Grootens KP; Faber G; van Beveren NJ; Been A; van den Brink T; Bak M; van Amelsvoort TAMJ; Ruissen A; Blanke C; Groen K; de Haan L; Sommer IEC
Trials; 2020 Feb; 21(1):147. PubMed ID: 32033579
[TBL] [Abstract][Full Text] [Related]
3. Effect of discontinuation v. maintenance of antipsychotic medication on relapse rates in patients with remitted/stable first-episode psychosis: a meta-analysis.
Kishi T; Ikuta T; Matsui Y; Inada K; Matsuda Y; Mishima K; Iwata N
Psychol Med; 2019 Apr; 49(5):772-779. PubMed ID: 29909790
[TBL] [Abstract][Full Text] [Related]
4. TAILOR - tapered discontinuation versus maintenance therapy of antipsychotic medication in patients with newly diagnosed schizophrenia or persistent delusional disorder in remission of psychotic symptoms: study protocol for a randomized clinical trial.
Stürup AE; Jensen HD; Dolmer S; Birk M; Albert N; Nielsen M; Hjorthøj C; Eplov L; Ebdrup BH; Mors O; Nordentoft M
Trials; 2017 Sep; 18(1):445. PubMed ID: 28962668
[TBL] [Abstract][Full Text] [Related]
5. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
6. Risk Factors for Psychotic Relapse After Dose Reduction or Discontinuation of Antipsychotics in Patients With Chronic Schizophrenia. A Meta-Analysis of Randomized Controlled Trials.
Bogers JPAM; Hambarian G; Walburgh Schmidt N; Vermeulen JM; de Haan L
Schizophr Bull; 2023 Jan; 49(1):11-23. PubMed ID: 36200866
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome after antipsychotic treatment discontinuation in functionally recovered first-episode nonaffective psychosis individuals: a 3-year naturalistic follow-up study.
Mayoral-van Son J; de la Foz VO; Martinez-Garcia O; Moreno T; Parrilla-Escobar M; Valdizan EM; Crespo-Facorro B
J Clin Psychiatry; 2016 Apr; 77(4):492-500. PubMed ID: 26759992
[TBL] [Abstract][Full Text] [Related]
8. Beyond Clinical Remission in First Episode Psychosis: Thoughts on Antipsychotic Maintenance vs. Guided Discontinuation in the Functional Recovery Era.
Alvarez-Jimenez M; O'Donoghue B; Thompson A; Gleeson JF; Bendall S; Gonzalez-Blanch C; Killackey E; Wunderink L; McGorry PD
CNS Drugs; 2016 May; 30(5):357-68. PubMed ID: 27106296
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic dose reduction and discontinuation versus maintenance treatment in people with schizophrenia and other recurrent psychotic disorders in England (the RADAR trial): an open, parallel-group, randomised controlled trial.
Moncrieff J; Crellin N; Stansfeld J; Cooper R; Marston L; Freemantle N; Lewis G; Hunter R; Johnson S; Barnes T; Morant N; Pinfold V; Smith R; Kent L; Darton K; Long M; Horowitz M; Horne R; Vickerstaff V; Jha M; Priebe S
Lancet Psychiatry; 2023 Nov; 10(11):848-859. PubMed ID: 37778356
[TBL] [Abstract][Full Text] [Related]
10. Randomised controlled trial of gradual antipsychotic reduction and discontinuation in people with schizophrenia and related disorders: the RADAR trial (Research into Antipsychotic Discontinuation and Reduction).
Moncrieff J; Lewis G; Freemantle N; Johnson S; Barnes TRE; Morant N; Pinfold V; Hunter R; Kent LJ; Smith R; Darton K; Horne R; Crellin NE; Cooper RE; Marston L; Priebe S
BMJ Open; 2019 Nov; 9(11):e030912. PubMed ID: 31780589
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of discontinuation from antipsychotic maintenance following first-episode schizophrenia and related disorders: a 10 year follow-up of a randomised, double-blind trial.
Hui CLM; Honer WG; Lee EHM; Chang WC; Chan SKW; Chen ESM; Pang EPF; Lui SSY; Chung DWS; Yeung WS; Ng RMK; Lo WTL; Jones PB; Sham P; Chen EYH
Lancet Psychiatry; 2018 May; 5(5):432-442. PubMed ID: 29551618
[TBL] [Abstract][Full Text] [Related]
12. Intermittent drug techniques for schizophrenia.
Sampson S; Mansour M; Maayan N; Soares-Weiser K; Adams CE
Cochrane Database Syst Rev; 2013 Jul; (7):CD006196. PubMed ID: 23881657
[TBL] [Abstract][Full Text] [Related]
13. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
[TBL] [Abstract][Full Text] [Related]
14. Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome.
Wunderink L; Nienhuis FJ; Sytema S; Slooff CJ; Knegtering R; Wiersma D
J Clin Psychiatry; 2007 May; 68(5):654-61. PubMed ID: 17503973
[TBL] [Abstract][Full Text] [Related]
15. Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults.
Van Leeuwen E; van Driel ML; Horowitz MA; Kendrick T; Donald M; De Sutter AI; Robertson L; Christiaens T
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013495. PubMed ID: 33886130
[TBL] [Abstract][Full Text] [Related]
16. Can antipsychotic dose reduction lead to better functional recovery in first-episode psychosis? A randomized controlled-trial of antipsychotic dose reduction. The reduce trial: Study protocol.
Weller A; Gleeson J; Alvarez-Jimenez M; McGorry P; Nelson B; Allott K; Bendall S; Bartholomeusz C; Koval P; Harrigan S; O'Donoghue B; Fornito A; Pantelis C; Paul Amminger G; Ratheesh A; Polari A; Wood SJ; van der El K; Ellinghaus C; Gates J; O'Connell J; Mueller M; Wunderink L; Killackey E
Early Interv Psychiatry; 2019 Dec; 13(6):1345-1356. PubMed ID: 30488637
[TBL] [Abstract][Full Text] [Related]
17. Continuing, reducing, switching, or stopping antipsychotics in individuals with schizophrenia-spectrum disorders who are clinically stable: a systematic review and network meta-analysis.
Ostuzzi G; Vita G; Bertolini F; Tedeschi F; De Luca B; Gastaldon C; Nosé M; Papola D; Purgato M; Del Giovane C; Correll CU; Barbui C
Lancet Psychiatry; 2022 Aug; 9(8):614-624. PubMed ID: 35753323
[TBL] [Abstract][Full Text] [Related]
18. Antiglucocorticoid and related treatments for psychosis.
Garner B; Phillips LJ; Bendall S; Hetrick SE
Cochrane Database Syst Rev; 2016 Jan; 2016(1):CD006995. PubMed ID: 26725721
[TBL] [Abstract][Full Text] [Related]
19. Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disorders.
Mahapatra J; Quraishi SN; David A; Sampson S; Adams CE
Cochrane Database Syst Rev; 2014 Jun; 2014(6):CD001470. PubMed ID: 24915451
[TBL] [Abstract][Full Text] [Related]
20. You say "schizophrenia" and I say "psychosis": Just tell me when I can come off this medication.
Zipursky RB; Odejayi G; Agid O; Remington G
Schizophr Res; 2020 Nov; 225():39-46. PubMed ID: 32115315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
